US frustration with pharmaceutical policy in Australia has grown in recent years, not just in relation to pricing but intellectual property and even biosimilars.

New Stories
-
Mayne officially opens US facility
April 20, 2018 - - Latest News -
The question is how and why now?
April 20, 2018 - - Latest News -
New report show rebates average 44% in New Zealand
April 20, 2018 - - Latest News -
Merck sells consumer health business
April 20, 2018 - - Latest News -
Shire rejects third bid from Takeda
April 20, 2018 - - Latest News -
PBS listing process descends into farce
April 19, 2018 - - Latest News -
A serious industry deserving of serious decisions
April 19, 2018 - - Comment